Pomalidomide-C6-CO2H is primarily utilized in the development and synthesis of novel pharmaceutical compounds, particularly in the field of oncology. It serves as a key intermediate in the creation of targeted cancer therapies, especially for the treatment of multiple myeloma and other hematologic malignancies. Its structure allows for modifications that enhance drug efficacy and reduce off-target effects, making it valuable in the design of immunomodulatory drugs. Additionally, it is employed in research to study its mechanism of action in inhibiting angiogenesis and inducing apoptosis in cancer cells, contributing to advancements in precision medicine.